Eisai Enters Biologics Arena With $325 Million Morphotek Acquisition
This article was originally published in The Pink Sheet Daily
Executive Summary
Japanese firm plans to grow U.S. sales to $4 billion via expanded sales force of 1,500 by 2011, Eisai tells “The Pink Sheet” DAILY.
You may also be interested in...
Morphotek’s Busy Year Continues With NCI Collaboration On Prostate Cancer Antibody
Company hopes monoclonal antibody identified by NCI will demonstrate utility in multiple cancer types.
Morphotek’s Busy Year Continues With NCI Collaboration On Prostate Cancer Antibody
Company hopes monoclonal antibody identified by NCI will demonstrate utility in multiple cancer types.
Eisai Strengthens Oncology Position With $3.9 Billion MGI Pharma Acquisition
MGI sale comes less than two weeks after the biopharma said it was exploring "strategic alternatives."